Compare EIG & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EIG | EVO |
|---|---|---|
| Founded | 2000 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 911.6M | 778.3M |
| IPO Year | 2006 | 2007 |
| Metric | EIG | EVO |
|---|---|---|
| Price | $48.94 | $1.92 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 143.4K | 40.5K |
| Earning Date | 04-29-2026 | 04-08-2026 |
| Dividend Yield | ★ 2.99% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | ★ $858,700,000.00 | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | $1.26 | $10.05 |
| P/E Ratio | $23.68 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $35.73 | $1.87 |
| 52 Week High | $52.59 | $4.27 |
| Indicator | EIG | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.83 | 41.02 |
| Support Level | $48.30 | $1.90 |
| Resistance Level | $52.32 | $2.20 |
| Average True Range (ATR) | 0.97 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 76.20 | 15.15 |
Employers Holdings Inc is a provider of workers' compensation insurance and services focused on small and mid-sized businesses engaged in low-to-medium hazard industries. Its customers are employers, and the insurance premiums that those employers pay to account for company revenue. Substantially all of the remaining revenue is generated through investments. The company operates exclusively in the United States, and it generates more than half of its business in California. By industry, the company has exposure to restaurants, which account for roughly a fourth of the total premiums the company earns. It operates as a single reportable segment, Insurance Operations through its wholly owned subsidiaries.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.